Antithrombotic management plan for cancer patients

In Germany Thrombosis occurs 470.000 timesevery year - as often as a new cancer is diagnosed. With 44.000 deadly lung artery embolisms every year, thrombosis is very dangerous.

Around 30 independent risk factors are known. One of the more important risk factors seems to be the amount of intracirculatory tissue factor molecules which is brought into circulation bound to the circulating epithelial cells.

Tissue factor is always active to start the coagulation process. Whether or not such cells are direct daughters or grand daughters of a cancer or derived from a metastasis or even are just waste from an inflammatory process doesn´t play a role - the additional risk directly depends on the amount of stimulation by the tissue factor molecules.

The Khorana score was very important in its hints to the phenomenon of increased incidence of thrombosis with cancer of different organ sources. However it combines the methodological problems of scores in general with looking after the influence of a surrogate through discreting eye glasses.

The thrombotrac approach came two steps further by looking directly into an effective mechanism and using real numbers instead of questionable a priori classifications. In thrombotrac, an algorithm puts the actual strengths and interactions of the risk factors into a model, using the simplest possible assumptions.

Therefore we all together could meditate about our way to get an antithrombotic management plan. I would be glad joining.

Dr. med Ulrich Pachmann

www.maintrac.com

SIMFO Spezielle Immunologie Forschung + Entwicklung GmbH
Peter Pachmann
Kurpromenade 2
95448 Bayreuth
Germany
T: +49 921 73005201
E: ppachmann@simfo.de

Simfo GmbH is a research and development facility with advanced expertise in personalized medicine, based in Bayreuth, Germany. It focuses particularly on the development of innovative analysis methods in haematological and oncological diagnostics in order to optimize personalized therapy. With maintrac®, simfo GmbH offers an analysis platform for the early detection of circulating tumor cells. This allows more rapid intervention options and therefore better treatment.

This release was published on openPR.